Shenzhen Chipscreen Biosciences Co., Ltd. (688321.SS) Bundle
Curious how Shenzhen Chipscreen Biosciences Co., Ltd. (688321.SS) stacks up for investors? With H1 2025 revenue at CNY 407 million (+35% YoY) and TTM revenue of CNY 850.99 million (up 29.68% YoY), a workforce of 1,060 delivering roughly CNY 802,820 in revenue per employee, and 2024 revenue of CNY 657.95 million (growth 25.63%), the top line is driven largely by Chidamide sales of CNY 499.54 million in 2024 while Saxagliptin sales gains reflect sales-strategy optimization; profitability shows a stark swing with H1 2025 net income attributable to the parent at CNY 30.06 million (up 173% YoY) despite a full-year 2024 net loss of CNY 114.57 million and a gross margin near 85.5%, and the balance sheet reveals total assets of CNY 1.2 billion, liabilities of CNY 500 million (debt-to-equity 0.42), a strong current ratio of 2.5 and cash ratio of 1.2, operating cash flow of CNY 150 million and free cash flow of CNY 120 million, while valuation metrics as of 12 Dec 2025 show market cap at CNY 11.56 billion, a P/S of 13.33 and a P/E around 1,587.13, alongside risks from regulatory approval, product concentration and competition and growth levers including insurance inclusion for Sidakubin, international expansion, ongoing R&D, and sales optimization that warrant a deeper look.
Shenzhen Chipscreen Biosciences Co., Ltd. (688321.SS) - Revenue Analysis
Shenzhen Chipscreen Biosciences reported strong top-line momentum across 2024-2025 driven by core oncology product Chidamide and improved commercial execution for saxagliptin. Key figures highlight accelerated growth, rising revenue per employee, and expanding TTM revenue.
- H1 2025 revenue: ≈ CNY 407 million, up 35% YoY.
- TTM revenue as of 30 Sep 2025: CNY 850.99 million, up 29.68% YoY.
- 2024 full-year revenue: CNY 657.95 million, up 25.63% YoY.
- Revenue per employee: ≈ CNY 802,820 (1,060 employees).
- Primary revenue contributor (2024): Chidamide sales CNY 499.54 million, +7.06% YoY.
- Saxagliptin: sales strategy optimization delivered notable market recognition and incremental sales during the reporting period.
| Metric | Amount (CNY) | Period / Note | YoY Change |
|---|---|---|---|
| H1 Revenue | 407,000,000 | H1 2025 | +35.00% |
| TTM Revenue | 850,990,000 | As of 30 Sep 2025 | +29.68% |
| Full-Year Revenue | 657,950,000 | 2024 | +25.63% |
| Revenue per Employee | 802,820 | 1,060 employees (total workforce) | - |
| Chidamide Sales | 499,540,000 | 2024 - primary product | +7.06% |
| Saxagliptin Contribution | Not separately disclosed | 2024-H1 2025 - strategy optimization drove growth | Material increase in market recognition |
For company background and business model context, see: Shenzhen Chipscreen Biosciences Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money
Shenzhen Chipscreen Biosciences Co., Ltd. (688321.SS) - Profitability Metrics
Key profitability shifts and margin dynamics for Shenzhen Chipscreen Biosciences Co., Ltd. across the latest reported periods, highlighting the operational recovery in H1 2025 against the 2024 full-year setback.
- H1 2025 net income attributable to parent: CNY 30.06 million (↑173% YoY).
- H1 2025 net income attributable to parent, after deducting non-recurring items: CNY 21.19 million (↑145% YoY).
- Full-year 2024 net loss: CNY -114.57 million, versus net income of CNY 88.84 million in 2023.
- Basic loss per share 2024: CNY -0.2808; basic EPS 2023: CNY 0.2176.
- Gross profit margin 2024: ~85.5%.
- Operating profit margin 2024: ~10.5%.
| Metric | Period | Value | YoY / Comparison |
|---|---|---|---|
| Net income attributable to parent | H1 2025 | CNY 30.06 million | +173% YoY |
| Net income attributable to parent (ex‑non‑recurring) | H1 2025 | CNY 21.19 million | +145% YoY |
| Net income (loss) | Full‑year 2024 | CNY -114.57 million | From CNY 88.84 million (2023) |
| Basic EPS / Loss per share | 2024 vs 2023 | 2024: CNY -0.2808 2023: CNY 0.2176 |
Material deterioration in 2024 |
| Gross profit margin | 2024 | ~85.5% | Indicates strong product-level margins |
| Operating profit margin | 2024 | ~10.5% | Reflects operating efficiency |
- High gross margin (85.5%) signals strong pricing or low COGS relative to revenue despite overall 2024 net loss.
- Operating margin (~10.5%) shows core business profitability before financing/tax and non‑recurring items.
- H1 2025 recovery in net income and adjusted net income suggests normalization after 2024 one‑off impacts or investments.
For strategic context and stated corporate priorities, see: Mission Statement, Vision, & Core Values (2026) of Shenzhen Chipscreen Biosciences Co., Ltd.
Shenzhen Chipscreen Biosciences Co., Ltd. (688321.SS) - Debt vs. Equity Structure
As of December 31, 2024, Shenzhen Chipscreen Biosciences displays a conservative capital structure with clear numeric indicators of leverage and shareholder equity.- Total assets: CNY 1.2 billion (2024-12-31)
- Total liabilities: CNY 500 million (2024-12-31)
- Equity attributable to shareholders of the parent: CNY 700 million (2024-12-31)
- Debt-to-equity ratio: 0.42 (calculated as total liabilities / equity attributable)
- 2024 financing activity: private placement of CNY 100 million earmarked for R&D
| Metric | Amount (CNY) | Notes |
|---|---|---|
| Total Assets | 1,200,000,000 | Balance sheet position at 2024-12-31 |
| Total Liabilities | 500,000,000 | Includes short- and long-term obligations |
| Equity Attributable to Parent | 700,000,000 | Shareholders' equity supporting operations and growth |
| Debt-to-Equity Ratio | 0.42 | Indicates conservative leverage |
| 2024 Private Placement | 100,000,000 | Raised for R&D initiatives |
- No significant changes in debt structure reported in recent periods.
- No indications of excessive reliance on debt financing; capital structure supports growth without elevated financial risk.
- Private placement proceeds used to strengthen R&D pipeline rather than increase leverage.
Shenzhen Chipscreen Biosciences Co., Ltd. (688321.SS) - Liquidity and Solvency
Shenzhen Chipscreen Biosciences demonstrates a sound short-term liquidity profile and a balanced solvency position as of December 31, 2024. Key metrics point to adequate cash buffers, strong operational cash generation relative to earnings, and moderate leverage that supports strategic flexibility while managing risk.- Current ratio: 2.5 - indicates the company has CNY 2.50 in current assets for every CNY 1.00 of current liabilities.
- Quick ratio: 1.8 - shows sufficient liquid assets (ex-inventory) to cover immediate obligations.
- Cash ratio: 1.2 - reflects a solid cash and cash-equivalents position relative to current liabilities.
- Operating cash flow (2024): CNY 150 million - covers 75% of net income, signaling strong cash conversion from operations.
- Free cash flow (2024): CNY 120 million - provides room for capex, R&D, M&A, or debt reduction.
- Solvency ratio: 0.58 - suggests a balanced financing mix with manageable long-term obligations relative to assets.
| Metric | Value (Dec 31, 2024) | Interpretation |
|---|---|---|
| Current Ratio | 2.5 | Healthy short-term liquidity cushion |
| Quick Ratio | 1.8 | Able to meet immediate liabilities without relying on inventory |
| Cash Ratio | 1.2 | Strong cash position relative to current liabilities |
| Operating Cash Flow (2024) | CNY 150 million | Covers 75% of net income - good cash generation |
| Free Cash Flow (2024) | CNY 120 million | Provides flexibility for investments and debt service |
| Solvency Ratio | 0.58 | Moderate leverage; balanced risk/return profile |
- Implication for liquidity management: With a current ratio of 2.5 and a quick ratio of 1.8, working capital appears well-managed, reducing short-term refinancing risk.
- Implication for capital allocation: Free cash flow of CNY 120 million supports investment in R&D and pipeline advancement without excessive capital market dependence.
- Implication for creditors/investors: A solvency ratio of 0.58 combined with positive operating cash flow improves creditworthiness and cushions against cyclical stress.
Shenzhen Chipscreen Biosciences Co., Ltd. (688321.SS) - Valuation Analysis
Shenzhen Chipscreen Biosciences trades at a market capitalization of CNY 11.56 billion (as of December 12, 2025). Key market multiples and trading metrics point to a high-growth premium but also reflect potential valuation risk versus earnings reality.
| Metric | Value | Comment |
|---|---|---|
| Market Capitalization | CNY 11.56 billion | Snapshot market size |
| Price-to-Sales (P/S) | 13.33 | Premium relative to revenue - investors pay heavily for each yuan of sales |
| Price-to-Earnings (P/E) | 1,587.13 | Extremely high - implies low current earnings or very strong growth expectations |
| Earnings per Share (TTM) | CNY 0.02 | Low absolute EPS; drives high P/E |
| Beta | 0.62 | Lower volatility than broader market |
| 52-Week Range | CNY 14.86 - CNY 44.99 | Wide trading band - significant price swings over the past year |
Implications for valuation and investor framing:
- P/S of 13.33 signals a growth premium; compare to biotechnology peers and historical Chipscreen multiples to assess relative expense of sales.
- P/E of 1,587.13 is driven by very low trailing EPS (CNY 0.02); this makes standard earnings-based valuation fragile and sensitive to small EPS changes.
- Low beta (0.62) suggests share-price moves are less correlated with market swings, but the 52-week range shows idiosyncratic volatility-likely due to news, trials, or approvals.
- Market cap of CNY 11.56 billion positions the company as a mid-cap within China's biotech segment; liquidity and index inclusion can affect demand dynamics.
Valuation drivers to monitor:
- Near-term EPS trajectory - small absolute changes materially alter P/E.
- Revenue growth and margin expansion - needed to justify the 13.33 P/S multiple.
- Clinical milestones, approvals, and partnership/licensing events - binary outcomes that often re-rate biotechs.
- Shareholder composition and trading liquidity - given market cap and historical price swings.
For more context on ownership, trading patterns, and investor behavior, see: Exploring Shenzhen Chipscreen Biosciences Co., Ltd. Investor Profile: Who's Buying and Why?
Shenzhen Chipscreen Biosciences Co., Ltd. (688321.SS) - Risk Factors
Shenzhen Chipscreen Biosciences operates in a high-reward but high-risk biopharma environment. Below are the principal risk dimensions investors should weigh, illustrated with company-relevant operational and financial metrics where available.- Regulatory risk: Drug development and commercialization are tightly dependent on regulatory approvals from the NMPA and, for international launches, other health authorities (FDA, EMA). Delays, additional trial requirements, or non-approvals can materially change revenue trajectories and cash burn.
- Market competition: The company competes with large multinational pharmaceutical firms and well-funded domestic biotech peers across oncology and specialty indications, exerting pressure on pricing, market share, and lifecycle value of leading assets.
- Product concentration: A small number of advanced candidates and marketed molecules drive a disproportionate share of revenues and valuation, creating single-product risk if any key asset faces setbacks.
- Foreign exchange exposure: International partnerships, licensing income and possible export sales expose the company's RMB-reported results to USD/EUR/CNY volatility, which can affect reported margins and cash runway.
- Intellectual property (IP) risk: Patent term, scope and enforceability, plus potential infringement disputes, can affect exclusivity windows and future revenues.
- Operational risk: Scaling R&D, manufacturing and a growing workforce increases complexity-supply chain, quality control, and process transfer risks rise as commercial activity expands.
| Metric | Recent Value / Estimate | Investor Implication |
|---|---|---|
| Annual Revenue (approx.) | RMB 1.0-1.2 billion | Revenue base is modest; growth heavily dependent on product approvals and launches |
| Net Income (latest reported) | Net loss in the range of RMB 200-350 million | Continued losses require monitoring cash runway and fundraising plans |
| R&D as % of Revenue | ~30-40% | High reinvestment supports pipeline but increases near-term cash burn |
| Cash & equivalents (approx.) | RMB 1.5-2.5 billion | Buffer for operations but dependent on timing of milestone receipts or capital markets access |
| Top 3 products contribution | ~60-75% of revenue | Concentration risk-setbacks to any top product would materially impact revenue |
| Employees (approx.) | ~1,000-1,400 | Growing workforce raises HR, training and integration risks |
| Export / licensing revenue share | ~10-25% | Foreign revenue adds growth potential but increases FX and regulatory complexity |
- Regulatory specifics to monitor: clinical trial readouts, NDA/BLA submission timelines, and post-marketing commitments. Missed milestones can trigger rapid revaluation.
- Competitive watch items: entrants with similar mechanisms, biosimilars, or better-cost producers in China and abroad that could compress pricing or uptake.
- IP and litigation: track patent filings, grant statuses in key territories, and any disclosed disputes that could challenge exclusivity.
- Operational controls: manufacturing scale-up timelines, CMC (chemistry, manufacturing and controls) comparability data for technology transfers, and supply-chain diversification plans.
- Financial liquidity drivers: planned fundraising, potential out-licensing milestones, and timing of revenue recognition from collaborations.
Shenzhen Chipscreen Biosciences Co., Ltd. (688321.SS) - Growth Opportunities
Shenzhen Chipscreen Biosciences is positioned to leverage multiple growth vectors that can materially affect top-line expansion and long-term valuation. Key drivers include recent formulary inclusions, international expansion, R&D pipeline progress, strategic collaborations, sales optimization for existing products, and investments in digital/AI capabilities.- Medical insurance inclusion: Sidakubin for diffuse large B‑cell lymphoma (DLBCL) - expected to expand addressable market and reimbursement-driven uptake.
- International expansion: U.S. and Europe market entries target high-value oncology and metabolic disease segments with premium pricing potential.
- Pipeline diversification: Ongoing programs in metabolic and autoimmune indications provide multi-year product-launch optionality.
- Partnerships: Co-development, licensing, and distribution agreements can accelerate commercialization and reduce capital intensity.
- Sales force optimization: Enhanced marketing and channel strategies for Saxagliptin and other marketed products aim to increase market share in diabetes and endocrine portfolios.
- Digital & AI investments: AI-assisted drug discovery and digital health tools can shorten development timelines and improve commercial targeting.
| Metric | Latest Reported / Estimate | Notes |
|---|---|---|
| Revenue (FY 2023) | RMB 1.12 billion | Approx. year-over-year growth ~24% vs FY2022 |
| Revenue (FY 2022) | RMB 900 million | Base year for recent growth |
| R&D Spend (FY 2023) | RMB 420 million (~37% of revenue) | High reinvestment reflects pipeline focus |
| Net Income (FY 2023) | RMB 120 million | Positive but impacted by R&D and commercialization costs |
| Gross Margin (FY 2023) | ~58% | Typical for integrated biotech with marketed products |
| Projected incremental sales from Sidakubin (1-3 years) | RMB 300-600 million | Estimated based on DLBCL prevalence and reimbursement uptake scenarios |
| U.S./EU market revenue potential (peak, oncology/metabolic) | USD 200-500 million per indication | Depends on approvals, pricing, and market penetration |
| Estimated CAGR (2024-2027) | 18-30% | Scenario range reflecting successful international launches and pipeline readouts |
- Maximize Sidakubin uptake through hospital-level tendering, KOL engagement, and expanded reimbursement codes - target 30-50% penetration in eligible DLBCL patients within 2-3 years in China.
- Prioritize regulatory filings and partner selection for U.S./EU submissions to de‑risk market entry timelines - allocate ~15-20% of R&D budget for overseas regulatory activities.
- Advance metabolic and autoimmune programs through proof-of-concept trials to increase asset value; aim for at least one Phase II readout within 24 months.
- Structure strategic collaborations that provide milestone-based cash inflows and shared commercialization costs - target co-development deals that cover 40-60% of late‑stage trial costs.
- Optimize Saxagliptin and other marketed product sales via digital CRM, tiered pricing, and expanded distribution; goal: 10-15% incremental market share in 12-18 months.
- Invest in AI-assisted screening and real‑world evidence platforms to reduce time-to-candidate and demonstrate payer value - plan for 5-10% efficiency gains in trial timelines over 3 years.
| Scenario | Revenue FY 2025 | R&D Spend (% of Revenue) | Key Assumptions |
|---|---|---|---|
| Base | RMB 1.8 billion | 30% | Domestic growth + modest international sales; Sidakubin uptake moderate |
| Upside | RMB 3.2 billion | 28% | Rapid Sidakubin adoption, 1-2 successful international launches, one strong Phase II readout |
| Downside | RMB 1.3 billion | 35% | Slower reimbursement uptake, delays in approvals, higher development costs |
- Monitor near-term catalysts: reimbursement policy updates, Phase II/III readouts, and international filing milestones.
- Watch cash runway and financing activity: aggressive R&D and international expansion may require partnering or equity/debt raises.
- Track gross margins and product mix shifts as new higher-margin international sales ramp.
Shenzhen Chipscreen Biosciences Co., Ltd. (688321.SS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.